MEK inhibitor can reverse the resistance to bevacizumab in A549 cells harboring Kirsten rat sarcoma oncogene homolog mutation

BACKGROUND: Bevacizumab (BV) is broadly used to treat a number of cancers; however, BV resistance mechanisms and strategies to overcome this resistance are yet to be determined. METHODS: We established xenograft mice models harboring Kirsten rat sarcoma oncogene homolog (KRAS) mutations based on the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yuan, Yan, Ping, Liu, Zhentao, Yang, Xiaodan, Wang, Yaping, Shen, Zhirong, Bai, Hua, Wang, Jie, Wang, Zhijie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846615/
https://www.ncbi.nlm.nih.gov/pubmed/27148412
http://dx.doi.org/10.1111/1759-7714.12325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846615/
https://www.ncbi.nlm.nih.gov/pubmed/27148412
http://dx.doi.org/10.1111/1759-7714.12325

Ejemplares similares